

GSK announces leadership changes in the US

19 August 2019 | News | By Sonali Wankhade

Bailey will be succeeded by Maya Martinez-Davis



GSK has announced that Jack Bailey, President US Pharmaceuticals has decided to step down from his role at the end of the year. Bailey will be succeeded by Maya Martinez-Davis, currently Regional President, Latin America Region at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany.

GSK continues to evolve its business. This includes an expanded pipeline and preparing launches of oncology medicines. Martinez-Davis brings outstanding experience of successfully bringing new specialty care treatments to patients. She is currently Regional President, Latin America Region and was previously SVP, Global Oncology at EMD Serono (Merck KGaA). Prior to this, she spent thirteen years at Pfizer leading various business units around the world including Oncology and Vaccines.

Luke Miels, President Global Pharmaceuticals, GSK, said, “Jack is an exceptional leader who has made a very significant contribution to the success of GSK during his decade of leadership in the US.”

“As we continue to grow and reshape our business globally, we are pleased to have found a leader in Maya who will bring a valuable US experience and deep therapy area expertise to expanding our specialty care capabilities and market presence.”

Commenting on his time at GSK, Jack Bailey said, “After more than a decade at GSK and nearly three decades in the life sciences industry, I look forward to the chance to explore my next professional chapter. I am enormously proud of every GSK US colleague who has worked so hard to both navigate an exceptionally dynamic operating environment while returning the US Affiliate to double digit revenue growth these past several years. I am confident the company will build upon the talent, culture and performance success of the US Affiliate as it now expands its portfolio into oncology.”

Martinez-Davis will join GSK in mid-September and will assume responsibility of the US Pharmaceuticals business at GSK on January 1, 2020. Bailey will remain as strategic consultant to GSK on the US external environment through 2020.